U.S. stock futures were slightly lower this morning, with the Dow Jones futures falling around 5 points on Wednesday. Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in pre-market trading following the company’s announcement of the U.S. Food and Drug Administration’s (FDA) approval of UDENYCA ONBODY for pegfilgrastim-cbqv. UDENYCA ONBODY is the company’s on-body injector presentation of UDENYCA (pegfilgrastim-cbqv), a pegfilgrastim biosimilar administered the day after chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia. Coherus BioScie…

Read More